دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Cardiac Arrest and Neurologic Recovery: Insights from the Case of Mr. Damar Hamlin
Romergryko G. Geocadin MD, FNCS, FAAN, FANA, Sachin Agarwal MD, MPH, Adeline L. Goss MD, Clifton W. Callaway MD, PhD, Megan Richie MD
doi : 10.1002/ana.26619
The association between brain injury after cardiac arrest and poor survival outcomes has led to longstanding pessimism. However, the publicly witnessed cardiac arrest, resuscitation, and acute management of Mr. Damar Hamlin and his favorable neurologic recovery provides some optimism.
Lecanamab Ushers in a New Era of Anti-Amyloid Therapy for Alzheimer's Disease
Erik S. Musiek MD, PhD, Eric McDade DO, David M. Holtzman MD
doi : 10.1002/ana.26643
Protective Effects of Lovastatin in a Population-Based ALS Study and Mouse Model
Collin J. Kreple MD, PhD, Susan Searles Nielsen PhD, Kathleen M. Schoch PhD, Tao Shen, Mark Shabsovich BS, Yizhe Song MBBS, MS, MPH, Brad A. Racette MD, Timothy M. Miller MD, PhD
doi : 10.1002/ana.26600
The objective of this study was to use a novel combined pharmacoepidemiologic and amyotrophic lateral sclerosis (ALS) mouse model approach to identify potential motor neuron protective medications.
Monkeypox-Associated Central Nervous System Disease: A Case Series and Review
Kelli M. Money MD PhD, T. Allen Barnett MD, Samuel Rapaka DO, Rebecca Osborn MD, Takashi Kitani MD, Daniel Fuguet MD, Faria Amjad MD, Jeffrey R. Clark BA, Debanjana Chakravarty PhD, Matthew J. Copeland DO, Justin M. Honce MD, Princy N. Kumar MD, Rebecca N. Kumar MD, Fady Mousa-Ibrahim DO, Bilaal Sirdar MD, Rafal Sobota MD, Mengxuan Tang MD, Maureen K. Bolon MD MS, Eric J. Russell MD, Michael Wilson MD, Carlo Tornatore MD, Ayush Batra MD, Kenneth L. Tyler MD, Daniel M. Pastula MD MHS
doi : 10.1002/ana.26597
Monkeypox virus (MPXV) disease has been declared a public health emergency by the World Health Organization, creating an urgent need for neurologists to be able to recognize, diagnosis, and treat MPXV-associated neurologic disease.
Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints
Mary M. Reilly MD, David N. Herrmann MD, Davide Pareyson MD, Steven S. Scherer MD, PhD, Richard S. Finkel MD, Stephan Züchner MD, Joshua Burns PhD, Michael E. Shy MD
doi : 10.1002/ana.26633
Heritable neurological disorders provide insights into disease mechanisms that permit development of novel therapeutic approaches including antisense oligonucleotides, RNA interference, and gene replacement.
Longitudinal Synaptic Density PET with 11C-UCB-J 6Â Months After Ischemic Stroke
Laura Michiels MD, PhD, Liselot Thijs PhD, Nathalie Mertens PhD, Marjan Coremans MSc, Mathieu Vandenbulcke MD, PhD, Geert Verheyden PhD, Michel Koole PhD, Koen Van Laere MD, PhD, Robin Lemmens MD, PhD
doi : 10.1002/ana.26593
The purpose of this study was to explore longitudinal changes in synaptic density after ischemic stroke in vivo with synaptic vesicle protein 2A (SV2A) positron emission tomography (PET).
The Role of Ascending Ventral-Tegmental Fibers for Recovery after Stroke
Jonas A. Hosp, Andrea Dressing, Anika Engesser, Volkmar Glauche, Dorothee Kümmerer, Ema B. Vaidelyte, Mariachristina Musso, Michel Rijntjes, Cornelius Weiller
doi : 10.1002/ana.26595
The integrity of cortical motor networks and their descending effector pathway (the corticospinal tract [CST]) is a major determinant motor recovery after stroke. However, this view neglects the importance of ascending tracts and their modulatory effects on cortical physiology. Here, we explore the role of such a tract that connects dopaminergic ventral tegmental midbrain nuclei to the motor cortex (the VTMC tract) for post-stroke recovery.
The Benefit of a Complete over a Successful Reperfusion Decreases with Time
Benjamin Maïer MD, PhD, Stephanos Finitsis MD, PhD, Mikael Mazighi MD, PhD, Bertrand Lapergue MD, PhD, Gaultier Marnat MD, Igor Sibon MD, PhD, Sebastien Richard MD, PhD, Alain Viguier MD, Christophe Cognard MD, PhD, Benjamin Gory MD, PhD, Jean-Marc Olivot MD, PhD, on behalf of the ETIS Registry Investigators
doi : 10.1002/ana.26599
Time from stroke onset to reperfusion (TSOR) is strongly associated with outcomes after endovascular treatment. A near-to-complete or complete reperfusion (modified Treatment in Cerebral Ischemia [mTICI] 2c–3) is associated with improved outcomes compared with a successful reperfusion (mTICI 2b).
Economic Evaluation of a Mobile Stroke Unit Service in Germany
Ana Sofia Oliveira Gonçalves MSc, Jessica L. Rohmann PhD, Marco Piccininni PhD, Tobias Kurth MD, ScD, Martin Ebinger MD, Matthias Endres MD, Erik Freitag MD, Peter Harmel MD, Irina Lorenz-Meyer MSc, Ira Rohrpasser-Napierkowski Dr. rer. nat., Reinhard Busse MD, Heinrich J. Audebert MD
doi : 10.1002/ana.26602
Lower global disability and higher quality of life among ischemic stroke patients was found to be associated with the dispatch of mobile stroke units (MSUs) among patients eligible for recanalizing treatments in the Berlin_Prehospital Or Usual Delivery of stroke care (B_PROUD) study. The current study assessed the cost-utility and cost-effectiveness of additional MSU dispatch using data from this prospective, controlled, intervention study.
Small Dense Low-Density Lipoprotein Cholesterol and Ischemic Stroke
Mie Balling MD, Børge G. Nordestgaard MD, DMSc, Anette Varbo MD, PhD, Anne Langsted MD, PhD, Pia R. Kamstrup MD, PhD, Shoaib Afzal MD, PhD, DMSc
doi : 10.1002/ana.26598
For decades, it has been suggested that small dense low-density lipoprotein (sdLDL) may be particularly atherogenic. High levels of sdLDL are associated with an increased risk of ischemic heart disease; however, the association of sdLDL with ischemic stroke has not been explored in a large prospective study on the general population.
Role of Enlarged Perivascular Space in the Temporal Lobe in Cerebral Amyloidosis
Han Kyu Na MD, Han-Kyeol Kim MD, Hye Sun Lee PhD, Mina Park MD, PhD, Jae Hoon Lee MD, PhD, Young Hoon Ryu MD, PhD, Hanna Cho MD, PhD, Chul Hyoung Lyoo MD, PhD
doi : 10.1002/ana.26601
Although growing evidence suggests that perivascular space (PVS) serves as a clearance route for amyloid and tau, the association between enlarged PVS (EPVS) and Alzheimer disease is highly inconsistent across studies. As the conventional visual rating systems for EPVS were insufficient to predict amyloid/tau/neurodegeneration (A/T/N) status, we developed a new rating scale for EPVS located in the temporal lobe (T-EPVS).
Rapid Eye Movement Sleep, Neurodegeneration, and Amyloid Deposition in Aging
Claire André PhD, Pierre Champetier MSc, Stéphane Rehel PhD, Elizabeth Kuhn MSc, Edelweiss Touron MSc, Valentin Ourry MSc, Brigitte Landeau MSc, Gwendoline Le Du MSc, Florence Mézenge BA, Shailendra Segobin PhD, Vincent de la Sayette MD, PhD, Denis Vivien PhD, Gaël Chételat PhD, Géraldine Rauchs PhD, the Medit-Ageing Research Group
doi : 10.1002/ana.26604
Rapid eye movement (REM) sleep is markedly altered in Alzheimer's disease (AD), and its reduction in older populations is associated with AD risk. However, little is known about the underlying brain mechanisms. Our objective was to investigate the relationships between REM sleep integrity and amyloid deposition, gray matter volume, and perfusion in aging.
Atrophy of the Cholinergic Basal Forebrain can Detect Presynaptic Cholinergic Loss in Parkinson's Disease
Nicola J. Ray PhD, Prabesh Kanel PhD, Nicolaas I. Bohnen MD, PhD
doi : 10.1002/ana.26596
Structural imaging of the cholinergic basal forebrain may provide a biomarker for cholinergic system integrity that can be used in motor and non-motor outcome studies in Parkinson's disease. However, no prior studies have validated these structural metrics with cholinergic nerve terminal in vivo imaging in Parkinson's disease. Here, we correlate cholinergic basal forebrain morphometry with the topography of vesicular acetylcholine transporter in a large Parkinson's sample.
Basal Ganglia Atrophy as a Marker for Prodromal X-Linked Dystonia-Parkinsonism
Henrike Hanssen MD, Cid C. E. Diesta MD, Marcus Heldmann PhD, Jackson Dy MD, Jeffrey Tantianpact MD, Julia Steinhardt PhD, Rosanna Sauza RN, Hans T. S. Manalo RN, Andreas Sprenger PhD, Charles Jourdan Reyes PhD, Raphael Tuazon MD, Björn-Hergen Laabs MSc, Aloysius Domingo MD, PhD, Raymond L. Rosales MD, Christine Klein MD, Thomas F. Münte MD, Ana Westenberger PhD, Jean Q. Oropilla MD, Norbert Brüggemann MD
doi : 10.1002/ana.26606
In neurodegenerative diseases, the characterization of the prodromal phase is essential for the future application of disease-modifying therapies. X-linked dystonia-parkinsonism is a hereditary neurodegenerative movement disorder characterized by severe adult-onset dystonia accompanied by parkinsonism.
Genome-Wide Analysis of Structural Variants in Parkinson Disease
Kimberley J. Billingsley PhD, Jinhui Ding PhD, Pilar Alvarez Jerez BSc, Anastasia Illarionova MSc, Kristin Levine MS, Francis P. Grenn BS, Mary B. Makarious BS, Anni Moore BS, Daniel Vitale MS, Xylena Reed PhD, Dena Hernandez PhD, Ali Torkamani PhD, Mina Ryten MD, PhD, John Hardy PhD, UK Brain Expression Consortium (UKBEC), Ruth Chia PhD, Sonja W. Scholz MD, PhD, Bryan J. Traynor MD PhD, Clifton L. Dalgard PhD, Debra J. Ehrlich MD, Toshiko Tanaka PhD, Luigi Ferrucci MD, PhD, Thomas G. Beach MD, PhD, Geidy E. Serrano PhD, John P. Quinn PhD, Vivien J. Bubb PhD, Ryan L Collins PhD, Xuefang Zhao PhD, Mark Walker PhD, Emma Pierce-Hoffman BS, Harrison Brand PhD, Michael E. Talkowski PhD, Bradford Casey PhD, Mark R Cookson PhD, Androo Markham MSc, Mike A. Nalls PhD, Medhat Mahmoud PhD, Fritz J Sedlazeck PhD, Cornelis Blauwendraat PhD, J. Raphael Gibbs PhD, Andrew B. Singleton PhD … See fewer authors
doi : 10.1002/ana.26608
Identification of genetic risk factors for Parkinson disease (PD) has to date been primarily limited to the study of single nucleotide variants, which only represent a small fraction of the genetic variation in the human genome. Consequently, causal variants for most PD risk are not known. Here we focused on structural variants (SVs), which represent a major source of genetic variation in the human genome.
β2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk
Bojing Liu PhD, Per Svenningsson MD, PhD, Jonas F. Ludvigsson MD, PhD, Cecilia Lundholm PhD, Johan Wallin MD, Henrik Larsson PhD, Arvid Sjölander PhD, Dylan M. Williams PhD, Nancy L. Pedersen PhD, Karin Wirdefeldt MD, PhD
doi : 10.1002/ana.26638
This study was undertaken to examine the association between montelukast use, β2-adrenoreceptor (β2AR) agonist use, and later Parkinson disease (PD).
Bradykinesia and Its Progression Are Related to Interhemispheric Beta Coherence
Kevin B. Wilkins PhD, Yasmine M. Kehnemouyi BS, Matthew N. Petrucci PhD, Ross W. Anderson PhD, Jordan E. Parker BA, Megan H. Trager BA, Raumin S. Neuville BS, Mandy M. Koop PhD, Anca Velisar MS, Zack Blumenfeld BS, Emma J. Quinn MS, Helen M. Bronte-Stewart MD, MSE
doi : 10.1002/ana.26605
Bradykinesia is the major cardinal motor sign of Parkinson disease (PD), but its neural underpinnings are unclear. The goal of this study was to examine whether changes in bradykinesia following long-term subthalamic nucleus (STN) deep brain stimulation (DBS) are linked to local STN beta (13–30 Hz) dynamics or a wider bilateral network dysfunction.
Time to Rebaseline Cognitive Performance in People with Multiple Sclerosis?
Christos Bakirtzis MD, PhD, Dawn W. Langdon PhD, Nikolaos Grigoriadis MD, PhD
doi : 10.1002/ana.26628
Type I Interferon Signature in NOTCH1-Related Leukoencephalopathy
Francesco Nicita MD, PhD, Lorena Travaglini PhD, Valentina Matteo BSc, Chiara Aiello PhD, Daniela Longo MD, Antonella Insalaco MD, Enrico Bertini MD, Giusi Prencipe PhD
doi : 10.1002/ana.26631
Reply to “Type I IFN Signature in NOTCH1-Related Leukoencephalopathy�
Dorit Verhoeven MD, Samantha A. M. Tromp MSc, Marjo S. van der Knaap MD, PhD, Taco W. Kuijpers MD, PhD
doi : 10.1002/ana.26629
Concomitant Alzheimer Disease Pathology in Parkinson Disease Dementia
Thomas F. Tropea DO, MPH, MTR, Isabela Albuja BS, Katheryn A. Q. Cousins PhD, David J. Irwin MD, Edward B. Lee MD, PhD, Alice S. Chen-Plotkin MD
doi : 10.1002/ana.26635
Reply to “Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia�
John R. Younce MD, W. R. Wayne Martin MD, Joel S. Perlmutter MD
doi : 10.1002/ana.26630
Aberrant GAP43 Gene Expression Is Alzheimer Disease Pathology-Specific
Jung-Min Pyun MD, PhD, Young Ho Park MD, PhD, Jiebiao Wang PhD, Paula J. Bice PhD, David A. Bennett MD, SangYun Kim MD, PhD, Andrew J. Saykin PsyD, Kwangsik Nho PhD
doi : 10.1002/ana.26637
Reply to: “Aberrant GAP43 Gene Expression Is Alzheimer Disease Pathology-Specific�
Guoyu Lan PhD, Tengfei Guo PhD
doi : 10.1002/ana.26639
Correction: GATA1-Mediated Transcriptional Regulation of the γ-Secretase Activating Protein Increases Aβ Formation in Down Syndrome
Jin Chu, Thomas Wisniewski, Domenico Pratico
doi : 10.1002/ana.26653
